OpenURL Connection Search

Select item for more details and to access through your institution.

An Experimental Study of the Microformability of Very Thin Materials.
Published in:
Experimental Mechanics, 2013, v. 53, n. 2, p. 155, doi. 10.1007/s11340-012-9623-3
By:
- Sène, N.;
- Balland, P.;
- Arrieux, R.;
- Bouabdallah, K.
Publication type:
Article
Kinematic Fields and Acoustic Emission Observations Associated with the Portevin Le Châtelier Effect on an Al–Mg Alloy.
Published in:
Experimental Mechanics, 2008, v. 48, n. 6, p. 741, doi. 10.1007/s11340-008-9125-5
By:
- Louche, H.;
- Bouabdallah, K.;
- Vacher, P.;
- Coudert, T.;
- Balland, P.
Publication type:
Article
Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features.
Published in:
Histopathology, 2006, v. 48, n. 4, p. 353, doi. 10.1111/j.1365-2559.2005.02323.x
By:
- Parrens, M.;
- Belaud-Rotureau, M.-A.;
- Fitoussi, O.;
- Carerre, N.;
- Bouabdallah, K.;
- Marit, G.;
- Dubus, P.;
- de Mascarel, A.;
- Merlio, J.-P.
Publication type:
Article
Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response.
Published in:
Bone Marrow Transplantation, 2013, v. 48, n. 11, p. 1484, doi. 10.1038/bmt.2013.86
By:
- Robles, M;
- Vigouroux, S;
- Tabrizi, R;
- Bouabdallah, K;
- Dilhuydy, M-S;
- Parrens, M;
- Leguay, T;
- Pigneux, A;
- Dumas, P-Y;
- Lascaux, A;
- Duclos, C;
- Marit, G;
- Milpied, N
Publication type:
Article
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia.
Published in:
Leukemia (08876924), 2012, v. 26, n. 10, p. 2254, doi. 10.1038/leu.2012.92
By:
- Rea, D;
- Etienne, G;
- Nicolini, F;
- Cony-Makhoul, P;
- Johnson-Ansah, H;
- Legros, L;
- Huguet, F;
- Tulliez, M;
- Gardembas, M;
- Bouabdallah, K;
- Rousselot, P;
- Cayuela, J-M;
- Guilhot, F;
- Mahon, F-X
Publication type:
Article
EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia.
Published in:
2007
By:
- Leguay, T.;
- Foucaud, C.;
- Parrens, M.;
- Fitoussi, O.;
- Bouabdallah, K.;
- Belaud-Rotureau, M. A.;
- Tabrizi, R.;
- Marit, G;
- Pigneux, A;
- Milpied, N
Publication type:
Letter
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 119, doi. 10.1002/hon.3163_81
By:
- Zinzani, P. L.;
- Mayer, J.;
- Trotman, J.;
- Bijou, F.;
- de Oliveira, A. C.;
- Song, Y.;
- Zhang, Q.;
- Merli, M.;
- Bouabdallah, K.;
- Ganly, P. S.;
- Zhang, H.;
- Johnson, R.;
- Garcia‐Sancho, A. M.;
- Pulla, M. Provencio;
- Trněný, M.;
- Yuen, S.;
- Assouline, S. E.;
- Auer, R.;
- Ivanoa, E.;
- Kim, P.
Publication type:
Article
CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 108, doi. 10.1002/hon.3163_69
By:
- Loyaux, R.;
- Sako, N.;
- Quang, V. Tran;
- Bachy, E.;
- Morschhauser, F.;
- Cartron, G.;
- Gressin, R.;
- Daguindau, N.;
- Le Gouill, S.;
- Wolfromm, A.;
- Bouabdallah, K.;
- Ysebaert, L.;
- Casasnovas, O.;
- Robe, C.;
- Delfau, M.;
- Dupuis, J.;
- De Leval, L.;
- Gaulard, P.;
- Sloma, I.;
- Lemonnier, F.
Publication type:
Article
Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1.
Published in:
Hematological Oncology, 2023, v. 41, p. 560, doi. 10.1002/hon.3164_420
By:
- Dreyling, M.;
- Santoro, A.;
- Mollica, L.;
- Leppä, S.;
- Follows, G. A.;
- Lenz, G.;
- Kim, W. S.;
- Nagler, A.;
- Panayiotidis, P.;
- Demeter, J.;
- Özcan, M.;
- Kosinova, M.;
- Provencio, M.;
- Magagnoli, M.;
- Bouabdallah, K.;
- Heo, D. S.;
- Diong, C. P.;
- Munoz, J.;
- Cao, A.;
- Hiemeyer, F.
Publication type:
Article
Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.
Published in:
Hematological Oncology, 2023, v. 41, p. 534, doi. 10.1002/hon.3164_397
By:
- Vic, S.;
- Thibert, J.;
- Bachy, E.;
- Cartron, G.;
- Gastinne, T.;
- Morschhauser, F.;
- Le Bras, F.;
- Bouabdallah, K.;
- Despas, F.;
- Bay, J.;
- Rubio, M.;
- Mohty, M.;
- Casasnovas, O.;
- Choquet, S.;
- Castilla‐Llorente, C.;
- Guidez, S.;
- Loschi, M.;
- Guffroy, B.;
- Carras, S.;
- La Rochelle, L. Drieu
Publication type:
Article
Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study.
Published in:
Hematological Oncology, 2023, v. 41, p. 512, doi. 10.1002/hon.3164_378
By:
- Tournilhac, O.;
- Altmann, B.;
- Friedrichs, B.;
- Bouabdallah, K.;
- Cartron, G.;
- Nickelsen, M.;
- Wulf, G.;
- Leclerc, M.;
- Vilatte, A.;
- Turlure, P.;
- Sanhès, L.;
- Houot, R.;
- Roussel, M.;
- de Leval, L.;
- Rosenwald, A.;
- Gaulard, P.;
- Dreger, P.;
- Glass, B.;
- Latière, C.;
- Damaj, G.
Publication type:
Article
Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination.
Published in:
Hematological Oncology, 2023, v. 41, p. 478, doi. 10.1002/hon.3164_352
By:
- Le Gouill, S.;
- Morschhauser, F.;
- Chiron, D.;
- Bouabdallah, K.;
- Cartron, G.;
- Casasnovas, O.;
- Rule, S.;
- Bodet‐Milin, C.;
- Herbaux, C.;
- Gastinne, T.;
- Callanan, M.;
- Tessoulin, B.
Publication type:
Article
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).
Published in:
Hematological Oncology, 2023, v. 41, p. 437, doi. 10.1002/hon.3164_322
By:
- Fornecker, L.;
- Delwail, V.;
- Thieblemont, C.;
- Ghesquieres, H.;
- Bouabdallah, K.;
- Tilly, H.;
- Le Calloch, R.;
- Morschhauser, F.;
- Costello, R.;
- Slama, B.;
- Gyan, E.;
- Chauchet, A.;
- Ngirabacu, M.;
- Durot, E.;
- Choquet, S.;
- Capdupuy, C.;
- Le Goff, M.;
- Voillat, L.;
- Snauwaert, S.;
- Amorim, S.
Publication type:
Article
REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort.
Published in:
Hematological Oncology, 2023, v. 41, p. 387, doi. 10.1002/hon.3164_281
By:
- Bommier, C.;
- Donzel, M.;
- Rossi, C.;
- Fornecker, L.;
- Bijou, F.;
- Chauchet, A.;
- Lebras, L.;
- Ysebaert, L.;
- Haioun, C.;
- Bouabdallah, K.;
- Morineau, N.;
- Gastinne, T.;
- Amorim, S.;
- Jardin, F.;
- Abraham, J.;
- Lamy de la Chapelle, T.;
- Gressin, R.;
- Fouillet, L.;
- Fruchart, C.;
- Morschhauser, F.
Publication type:
Article
Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study.
Published in:
Hematological Oncology, 2023, v. 41, p. 338, doi. 10.1002/hon.3164_241
By:
- Sako, N.;
- Delfau, M.;
- Bachy, E.;
- Morschhauser, F.;
- Cartron, G.;
- Casasnovas, O.;
- Gressin, R.;
- Daguindau, N.;
- Tournilhac, O.;
- Bouabdallah, K.;
- Le Gouill, S.;
- Andre, M.;
- Robe, C.;
- Dupuis, J.;
- De Leval, L.;
- Gaulard, P.;
- Lemonnier, F.
Publication type:
Article
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 151, doi. 10.1002/hon.3163_100
By:
- Sarkozy, C.;
- Thieblemont, C.;
- Oberic, L.;
- Moreau, A.;
- Bouabdallah, K.;
- Damaj, G.;
- Gastine, T.;
- Ribrag, V.;
- Casasnovas, O.;
- Haioun, C.;
- Houot, R.;
- Jardin, F.;
- Van Den Neste, E.;
- Cheminant, M.;
- Morschhauser, F.;
- Callana, M.;
- Ghesquieres, H.;
- Gressin, R.;
- Hermine, O.;
- Le Gouill, S.
Publication type:
Article
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY (EUDRACT NUMBER: 2015‐005612‐15)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.88_2880
By:
- Maerevoet, M.;
- Casasnovas, O.;
- Cartron, G.;
- Morschhauser, F.;
- Thieblemont, C.;
- Bouabdallah, K.;
- Feugier, P.;
- Szablewski, V.;
- Becker, S.;
- Tilly, H.
Publication type:
Article
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY (EUDRACT NUMBER: 2015‐005612‐15)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.87_2880
By:
- Maerevoet, M.;
- Casasnovas, O.;
- Cartron, G.;
- Morschhauser, F.;
- Thieblemont, C.;
- Bouabdallah, K.;
- Feugier, P.;
- Szablewski, V.;
- Becker, S.;
- Tilly, H.
Publication type:
Article
GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.192_2880
By:
- Paunescu, A.‐C.;
- Paget, J.;
- Bergman, C. Copie;
- Malak, S.;
- Le Gouill, S.;
- Ribrag, V.;
- Bouabdallah, K.;
- Sibon, D.;
- Rumpold, G.;
- Preau, M.;
- Mounier, N.;
- Haioun, C.;
- Jardin, F.;
- Besson, C.
Publication type:
Article
IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.137_2880
By:
- Sibon, D;
- Bisig, B;
- Bonnet, C;
- Bachy, E;
- Cavalieri, D;
- Fataccioli, V;
- Drieux, F;
- Bruneau, J;
- Lemonnier, F;
- Bossard, C;
- Bouabdallah, K;
- Parrens, M;
- Damaj, G;
- Tournilhac, O;
- Jais, J. P;
- Gaulard, P;
- de Leval, L
Publication type:
Article
BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.111_2880
By:
- Gastinne, T.;
- Bouabdallah, K.;
- Moatti, H.;
- Tessoulin, B.;
- Shiano del colella, J. M.;
- Lamy, T.;
- Casasnovas, O.;
- Borel, C.;
- Stamatoullas, A.;
- Gac, A. C.;
- Chaoui, D.;
- Feugier, P.;
- Delmer, A.;
- Bonnet, C.;
- Fornecker, Luc‐M.;
- Lazarovici, J.;
- Le Bras, F.;
- Ghesquieres, H.;
- Meignan, M.;
- Traverse Glehen, A.
Publication type:
Article
FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 99, doi. 10.1002/hon.64_2629
By:
- Tournilhac, O.;
- Truemper, L.;
- Ziepert, M.;
- Bouabdallah, K.;
- Nickelsen, M.;
- Maury, S.;
- Reimer, P.;
- Jaccard, A.;
- Herr, W.;
- Wilhelm, M.;
- Cartron, G.;
- Wulf, G.;
- Sanhes, L.;
- Dreger, P.;
- Lamy, T.;
- Kroschinsky, F.;
- Lindemann, H.;
- Roussel, M.;
- Viardot, A.;
- Sibon, D.
Publication type:
Article
FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 224, doi. 10.1002/hon.39_2630
By:
- Ferrero, S.;
- Ladetto, M.;
- Beldjord, K.;
- Drandi, D.;
- Stelitano, C.;
- Bernard, S.;
- Castagnari, B.;
- Bouabdallah, K.;
- Cesaretti, M.;
- Alvarez, I.;
- Gressin, R.;
- Ponzoni, M.;
- Tripodo, C.;
- Traverse‐Glehen, A.;
- Baseggio, L.;
- Liberati, A.;
- Merli, M.;
- Tessoulin, B.;
- Patti, C.;
- Cabras, M.
Publication type:
Article
OUTCOME OF PATIENTS WITH C‐MYC REARRANGED DIFFUSE LARGE B CELL LYMPHOMA ASSOCIATED OR NOT WITH BCL2 AND/OR BCL6 REARRANGEMENT: A MULTICENTRIC AND RETROSPECTIVE STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 355, doi. 10.1002/hon.17_2631
By:
- Favre, S.;
- Botella‐Garcia, C.;
- Bijou, F.;
- Deau‐Fisher, B.;
- Banos, A.;
- Rispal, P.;
- Saint‐Lézer, A.;
- Fitoussi, O.;
- Lifermann, F.;
- Labouré, G.;
- Dagada, C.;
- Milpied, N.;
- Bouabdallah, K.
Publication type:
Article
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 44, doi. 10.1002/hon.14_2629
By:
- Le Gouill, S.;
- Beldi‐Ferchiou, A.;
- Cacheux, V.;
- Salles, G.;
- Canioni, D.;
- Bodet‐Milin, C.;
- Alcantara, M.;
- Delwail, V.;
- Gastinne, T.;
- Thieblemont, C.;
- Maisonneuve, H.;
- Lamy de la Chapelle, T.;
- Oberic, l.;
- Bouabdallah, K.;
- Ribrag, V.;
- Delfau‐Larue, M.;
- Macintyre, E.;
- Hermine, O.
Publication type:
Article
FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 99, doi. 10.1002/hon.64_2629
By:
- Tournilhac, O.;
- Truemper, L.;
- Ziepert, M.;
- Bouabdallah, K.;
- Nickelsen, M.;
- Maury, S.;
- Reimer, P.;
- Jaccard, A.;
- Herr, W.;
- Wilhelm, M.;
- Cartron, G.;
- Wulf, G.;
- Sanhes, L.;
- Dreger, P.;
- Lamy, T.;
- Kroschinsky, F.;
- Lindemann, H.;
- Roussel, M.;
- Viardot, A.;
- Sibon, D.
Publication type:
Article
FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 224, doi. 10.1002/hon.39_2630
By:
- Ferrero, S.;
- Ladetto, M.;
- Beldjord, K.;
- Drandi, D.;
- Stelitano, C.;
- Bernard, S.;
- Castagnari, B.;
- Bouabdallah, K.;
- Cesaretti, M.;
- Alvarez, I.;
- Gressin, R.;
- Ponzoni, M.;
- Tripodo, C.;
- Traverse‐Glehen, A.;
- Baseggio, L.;
- Liberati, A.;
- Merli, M.;
- Tessoulin, B.;
- Patti, C.;
- Cabras, M.
Publication type:
Article
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 44, doi. 10.1002/hon.14_2629
By:
- Le Gouill, S.;
- Beldi‐Ferchiou, A.;
- Cacheux, V.;
- Salles, G.;
- Canioni, D.;
- Bodet‐Milin, C.;
- Alcantara, M.;
- Delwail, V.;
- Gastinne, T.;
- Thieblemont, C.;
- Maisonneuve, H.;
- Lamy de la Chapelle, T.;
- Oberic, l.;
- Bouabdallah, K.;
- Ribrag, V.;
- Delfau‐Larue, M.;
- Macintyre, E.;
- Hermine, O.
Publication type:
Article
OUTCOME OF PATIENTS WITH C‐MYC REARRANGED DIFFUSE LARGE B CELL LYMPHOMA ASSOCIATED OR NOT WITH BCL2 AND/OR BCL6 REARRANGEMENT: A MULTICENTRIC AND RETROSPECTIVE STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 355, doi. 10.1002/hon.17_2631
By:
- Favre, S.;
- Botella‐Garcia, C.;
- Bijou, F.;
- Deau‐Fisher, B.;
- Banos, A.;
- Rispal, P.;
- Saint‐Lézer, A.;
- Fitoussi, O.;
- Lifermann, F.;
- Labouré, G.;
- Dagada, C.;
- Milpied, N.;
- Bouabdallah, K.
Publication type:
Article
COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1).
Published in:
Hematological Oncology, 2017, v. 35, p. 119, doi. 10.1002/hon.2437_107
By:
- Dreyling, M.;
- Santoro, A.;
- Mollica, L.;
- Leppä, S.;
- Follows, G.A.;
- Lenz, G.;
- Kim, W.;
- Nagler, A.;
- Panayiotidis, P.;
- Demeter, J.;
- Özcan, M.;
- Kosinova, M.;
- Bouabdallah, K.;
- Morschhauser, F.;
- Stevens, D.A.;
- Trevarthen, D.;
- Giurescu, M.;
- Liu, L.;
- Koechert, K.;
- Peña, C.
Publication type:
Article
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial.
Published in:
Hematological Oncology, 2017, v. 35, p. 62, doi. 10.1002/hon.2437_49
By:
- Zinzani, P.;
- Thieblemont, C.;
- Melnichenko, V.;
- Osmanov, D.;
- Bouabdallah, K.;
- Walewski, J.;
- Majlis, A.;
- Fogliatto, L.;
- Caballero Barrigón, M.D.;
- Christian, B.;
- Gulbas, Z.;
- Özcan, M.;
- Salles, G.A.;
- Shipp, M.A.;
- Balakumaran, A.;
- Chlosta, S.;
- Chatterjee, A.;
- Armand, P.
Publication type:
Article
OBINUTUZUMAB PLUS IBRUTINIB IN RELAPSE/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS: FIRST RESULTS OF THE OASIS PHASE I TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 208, doi. 10.1002/hon.2438_73
By:
- Le Gouill, S.;
- Morschhauser, F.;
- Bouabdallah, K.;
- Cartron, G.;
- Casasnovas, O.;
- Davies, A.;
- Chiron, D.;
- Rule, S.
Publication type:
Article
Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group.
Published in:
Hematological Oncology, 2017, v. 35, p. 209, doi. 10.1002/hon.2438_74
By:
- Le Gouill, S.;
- Thieblemont, C.;
- Oberic, L.;
- Moreau, A.;
- Bouabdallah, K.;
- Dartigeas, C.;
- Damaj, G.;
- Gastinne, T.;
- Ribrag, V.;
- Feugier, P.;
- Casasnovas, O.;
- Zerazhi, H.;
- Haioun, C.;
- Maisonneuve, H.;
- Van Den Neste, E.;
- Tournilhac, O.;
- Le Dû, K.;
- Morschhauser, F.;
- Cartron, G.;
- Fornecker, L.
Publication type:
Article
Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.
Published in:
2021
By:
- Manson, G.;
- Brice, P.;
- Herbaux, C.;
- Silva, M. G.;
- Bouabdallah, K.;
- Deau, B.;
- Bouteloup, J.;
- Schiano, J. M.;
- Nicolas-Virelizier, E.;
- Maerevoet, M.;
- Ghesquieres, H.;
- Stamatoullas, A.;
- Antier, C.;
- Carlo-Stella, C.;
- de Charette, M.;
- Poizeau, F.;
- Dercle, L.;
- Houot, Roch
Publication type:
Correction Notice
Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 4, p. 1144, doi. 10.1007/s00259-020-05015-2
By:
- Manson, G.;
- Brice, P.;
- Herbaux, C.;
- Silva, M. G.;
- Bouabdallah, K.;
- Deau, B.;
- Bouteloup, J.;
- Schiano, J. M.;
- Nicolas-Virelizier, E.;
- Maerevoet, M.;
- Ghesquieres, H.;
- Stamatoullas, A.;
- Antier, C.;
- Carlo-Stella, C.;
- de Charette, M.;
- Poizeau, F.;
- Dercle, L.;
- Houot, Roch
Publication type:
Article
Erythema annulare centrifugum revealing chronic lymphocytic leukaemia.
Published in:
2007
By:
- Stokkermans-Dubois, J.;
- Beylot-Barry, M.;
- Vergier, B.;
- Bouabdallah, K.;
- Doutre, M. S.
Publication type:
Letter
Mantle Cell Lymphoma: Individualizing Therapy.
Published in:
Lymphoma & Chronic Lymphocytic Leukemias, 2015, n. 5, p. 1, doi. 10.4137/LCLL.S13724
By:
- Bouabdallah, K.;
- Milpied, N.
Publication type:
Article

Found: 37